Amici Capital’s Travere Therapeutics TVTX Stock Holding History

Amici Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-340,400	Closed	-$4.65M	–	132
2016 Q1	$4.65M	Buy	+340,400	New	+$5.16M	0.55%	44

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Amici Capital's TVTX Position: Q1 2017 in Review

Amici Capital sold out of Travere Therapeutics (TVTX) in Q1 2017, closing a stake of 243,930 shares — an estimated $4.62M sold.

Amici Capital first reported a position in TVTX in Q2 2014 and held it in 11 quarters. The position peaked at $37.5M in Q2 2015. 114 funds tracked by Wall St. Rank hold TVTX as of Q1 2017.

Amici Capital reported no remaining Travere Therapeutics position as of Q1 2017 after selling out during the quarter.
Amici Capital sold 243,930 Travere Therapeutics shares in Q1 2017, an estimated $4.62M.
Amici Capital first reported a position in Travere Therapeutics in Q2 2014 and held it in 11 quarters.
Amici Capital's Travere Therapeutics position peaked at $37.5M in Q2 2015.
114 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2017.

Based on Amici Capital's 13F filing for Q1 2017.